重症喘息における標的治療薬（生物製剤）：NPS+（米国）

米国のアレルギー専門医や呼吸器専門医が喘息を治療する際には、さまざまな選択肢があります。これらの選択肢の中には、明らかに他よりも高いロイヤリティと満足度を得ているものがありますが、それはなぜでしょうか。当レポートでは、医師の選択を促す主な要因、各主要ブランドの競合薬との比較、米国における主要な喘息治療薬に関する洞察などをまとめています。

レポートの内容

• ブランド別NPSスコアの比較
• 医師は特定のブランドにどの程度忠実か
• 医師の心に響くブランドメッセージ
• 医師の選択を促す主な要因
• 主要ブランドの市場シェア
• 各主要ブランドの競合他社との比較
• ブランド満足度が低いためにスイッチングしやすいブランド

主要ブランド

There are various options available to US allergists and pulmonologists treating asthma. Clearly, some of these options achieve greater levels of loyalty and satisfaction than others, but why? What are the key factors driving physician choice, and how does each of the leading brands compare to its competitors? Gain insights into leading asthma therapies in the US.

Key Questions Answered:

• 1. How do NPS scores by brand compare?
• 2. How loyal are physicians to specific brands?
• 3. What brand messages resonate with physicians?
• 4. What are the key factors driving physician choice?
• 5. What is the market share of leading brands?
• 6. How does each of the leading brands compare to its competitors?
• 7. Which brands are vulnerable to switching due to low brand satisfaction?

Key Brands

Methodology

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.